Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03261817
Other study ID # 2016-A00930-51
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 29, 2017
Est. completion date June 22, 2021

Study information

Verified date July 2021
Source University Hospital, Caen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, an APA program by web (e-APA) will be offered to two groups of participants (21 patients and 21 healthy volunteers (HV)) in remote video (use of the SAPATIC (Santé Activités Physiques Adaptées utilisant les Technologies de l'Information et de la Communication) platform developed by the company V@SI). At the same time, two control groups, a group of 21 patients and a group of 21 HV will undergo an health education program (HE) through the collaborative SAPATIC health platform of V@Si and will constitute the control groups. The content of the APA sessions will be administered by V@Si. This program offers content aimed to improve aerobic capacity and muscular strength while relying on the motivation of the participants


Description:

The main objective is to demonstrate that APA can improve cerebral plasticity in patients with schizophrenic or schizoaffective disorders (SCZ), reflected by an increase in the overall volume of hippocampus. The secondary objectives will also be to assess the impact of APA on the SCZ compared to the HV: 1. on other cerebral variables (changes in the different subregions of the hippocampus (Cornu Ammonis (CA: CA1,CA2-3-4), subiculum and dentate gyrus), cortical thickness, N-acetyl aspartate (NAA) and glutamate as well as changes in the white matter through the diffusion markers (fractional anisotropy, radial diffusivity and mean diffusivity in the frontomedial-hippocampal fibers) and cerebral irrigation 2. on physiological variables (neuromuscular, cardiovascular (heart rate variability) and aerobic) 3. on cognitive variables by measuring working memory, episodic memory, attentional and executive functions 4. on circadian rhythms (temperature, actimetry and wake-sleep cycle) 5. on the clinical status of patients (severity of symptoms, quality of life, level of activity and physical abilities). 6. on biological variables (fasting glucose, triglycerides, total cholesterol, High-density lipoprotein cholesterol (HDLc), Low-density lipoprotein cholesterol (LDLc)


Recruitment information / eligibility

Status Terminated
Enrollment 62
Est. completion date June 22, 2021
Est. primary completion date June 22, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: Patients: - Be over 18 years of age and under 60 years of age - with schizophrenia or schizoaffective disorder according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition) criteria established with a semi-structured interview (Mini International Neuropsychiatric Interview, French version 5.0.0). - The possibility of receiving each of the 2 interventions (APA or HE) - No change in psychotropic drugs (antidepressants, antipsychotics or mood regulators) during the 2 months prior to inclusion for patients. - Collecting the signature of informed consent. - The need to be affiliated to a medical welfare - The agreement of the guardian or trustee in case of a protected major Healthy Volunteers: - between 18 and 60 years old - The possibility of receiving each of the 2 interventions (APA or HE) - Collecting the signature of informed consent. - The need to be affiliated to a medical welfare Exclusion Criteria: Patients with only one of the non-inclusion criteria may not be eligible to participate in the research. These criteria are: - Age under 18 or over 60 years old - Pregnancy - The inclusion of the patient in another biomedical research protocol (during the present study) - Patients with progressive neurological disease - Patients with contraindications to MRI (including electronic or metal implants) - Patients who refused to wear earplugs during the MRI examination - Patients with a physical contraindication to physical activity (moderate to severe heart failure, severe valvular disease, unstable coronary disease, acute pulmonary embolism or untreated deep venous thrombosis, uncontrolled hypertension, pulmonary arterial hypertension, treaty) - Neuromuscular pathologies, severe sensory and / or motor neuropathy - Rheumatic and articular pathologies; Rheumatologic / orthopedic problems or bone lesions at risk of fracture contraindicating physical activity - History of stroke or myocardial infarction less than 6 months old at the selection visit Healthy Volunteers Participants with only one of the non-inclusion criteria may not be eligible to participate in the research. These criteria are: - Age under 18 or over 60 years old - Pregnancy - Inclusion of the participant in another biomedical research protocol (during this study) - Participants with progressive neurological disease - Participants with a contraindication to MRI (including electronic or metal implants) - Participants refused to wear ear plugs during the MRI examination - Participants with life-long schizophrenia or schizoaffective disorder according to the DSM-IV criteria established with a semi-structured interview (Mini International Neuropsychiatric Interview, MINI; French version 5.0.0). - Presence of cardiovascular pathologies contraindicating physical activity (moderate to severe heart failure, severe valvular disease, unstable coronary disease, acute pulmonary embolism or untreated deep venous thrombosis, uncontrolled hypertension, pulmonary arterial hypertension, rhythm disorder untreated) - Neuromuscular pathologies, severe sensory and / or motor neuropathy - Rheumatic and articular diseases, rheumatological / orthopedic problems or fracture risk bone lesions - History of stroke or myocardial infarction less than 6 months old at the selection visit

Study Design


Intervention

Behavioral:
Physical activity (APA)
2 sessions a week of 1 hour during 16 weeks. APA exercises by web will be aerobic type associated with muscle toning program; Activities will combine relaxation techniques, body expression and muscle relaxation (yoga, stretching, relaxation, step etc ...). The intensity of the activities will be individualized for each participant according to his/her physical condition
Health Education program (HE)
2 sessions a week of 1 hour during 16 weeks HE by web will be delivered and was composed of information on the main mental disorders, the benefits of physical activity, healthy lifestyle (dietary balance, sleep cycle, stress management), alcohol, drug, tobacco and cardiovascular risk factors

Locations

Country Name City State
France Caen University Hospital Caen

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Caen Centre Hospitalier du Rouvray

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary hippocampal volumes The primary endpoint is the right and left hippocampal volumes at Day 127 +/- 8 days or after 10 sessions of APA if premature cessation of treatment
Secondary Cerebral variables changes in the different subregions of the hippocampus (CA1, CA2-3-4, subiculum and dentate gyrus, cortical thickness, N-acetyl aspartate (NAA) and glutamate as well as changes in the white matter through the diffusion markers (fractional anisotropy, radial diffusivity and mean diffusivity in the frontomedial-hippocampal fibers) and cerebral irrigation at Day 127 +/- 8 days or after 10 sessions of APA if premature cessation of treatment
Secondary Physiological variables neuromuscular, cardiovascular (heart rate variability) and aerobic (VO2) at Day 127 +/- 8 days or after 10 sessions of APA if premature cessation of treatment
Secondary Circadian rhythms temperature, actimetry and wake-sleep cycle at Day 127 +/- 8 days or after 10 sessions of APA if premature cessation of treatment
Secondary Clinical status severity of symptoms, quality of life, level of activity and physical abilities at Day 127 +/- 8 days or after 10 sessions of APA if premature cessation of treatment
Secondary Biological variables fasting glucose, triglycerides, total cholesterol, HDLc, LDLc at Day 127 +/- 8 days or after 10 sessions of APA if premature cessation of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A
Completed NCT02304432 - Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine Early Phase 1